The prospect of a new asset class in psychedelic medicine and mental health technologies

Greg Kubin, a general partner at PsyMed Ventures, a VC fund focused on psychedelic therapeutics and other mental health technologies, joins the program to offer his insights on the biotech and pharmaceutical industries move into treating depression, anxiety, PTSD and other psychological ailments with the clinical use of MDMA, psilocybin, LSD, ketamine and other naturally occurring and synthetic treatments. (05/2022)

Forgot your username or password?